The Experts below are selected from a list of 48 Experts worldwide ranked by ideXlab platform

Alfred Königsrainer - One of the best experts on this subject based on the ideXlab platform.

  • simvastatin reduces tumor cell adhesion to human peritoneal mesothelial cells by decreased expression of vcam 1 and β1 integrin
    International Journal of Oncology, 2011
    Co-Authors: Britta Janina Wagner, Stefan Löb, Dennis Lindau, Helen Hörzer, Brigitte Gückel, Gerd Klein, Jörg Glatzle, Hans-georg Rammensee, Björn L.d.m. Brücher, Alfred Königsrainer
    Abstract:

    Peritoneal carcinomatosis describes Cancer metastasis onto the surface of the Peritoneum. It is frequently caused by ovarian and colorectal Cancer. Once a tumor has penetrated the Peritoneum, Cancer cells disseminate into the abdominal cavity. Additionally, surgery can account for the spread of free tumor cells. Their subsequent adhesion to mesothelial cells (HMCs) initiates peritoneal carcinomatosis. Therefore, this study analyzed the effect of simvastatin on tumor cell adherence. HMCs were isolated from human greater omentum. Fluorescence-labeled tumor cells (SKOV-3, OvCar-29, OAW42, FraWu; ovarian/HT29; colorectal) were incubated on confluent mesothelial monolayers with 10 microM simvastatin for 48 h. Adhesion was quantified using a fluorescence reader. Expression of the adhesion molecules VCAM-1, ICAM-1 and beta1 integrin chain under the influence of simvastatin 0.1-100 microM for 24-72 h was analyzed using flow cytometry. Simvastatin significantly reduced the adhesion of all ovarian Cancer cells and HT29 to HMCs (PVCAM-1 on HMCs. ICAM-1 and beta1 integrin chain expression on ovarian Cancer cells was also clearly reduced. By contrast, the expression of the analyzed adhesion molecules on HT29 cells remained unchanged. Simvastatin clearly inhibits tumor cell adhesion to HMCs. In the case of ovarian Cancer cell lines it appears to be mediated by decreased expression of both VCAM-1 on HMCs and the integrin alpha4beta1 on tumor cells. As an example of adhesion molecule down-regulating drugs, simvastatin may provide a novel therapeutic approach to the prevention of peritoneal carcinomatosis.

  • Simvastatin reduces tumor cell adhesion to human peritoneal mesothelial cells by decreased expression of VCAM-1 and β1 integrin
    International journal of oncology, 2011
    Co-Authors: Britta Janina Wagner, Stefan Löb, Dennis Lindau, Helen Hörzer, Brigitte Gückel, Gerd Klein, Jörg Glatzle, Hans-georg Rammensee, Björn L.d.m. Brücher, Alfred Königsrainer
    Abstract:

    Peritoneal carcinomatosis describes Cancer metastasis onto the surface of the Peritoneum. It is frequently caused by ovarian and colorectal Cancer. Once a tumor has penetrated the Peritoneum, Cancer cells disseminate into the abdominal cavity. Additionally, surgery can account for the spread of free tumor cells. Their subsequent adhesion to mesothelial cells (HMCs) initiates peritoneal carcinomatosis. Therefore, this study analyzed the effect of simvastatin on tumor cell adherence. HMCs were isolated from human greater omentum. Fluorescence-labeled tumor cells (SKOV-3, OvCar-29, OAW42, FraWu; ovarian/HT29; colorectal) were incubated on confluent mesothelial monolayers with 10 microM simvastatin for 48 h. Adhesion was quantified using a fluorescence reader. Expression of the adhesion molecules VCAM-1, ICAM-1 and beta1 integrin chain under the influence of simvastatin 0.1-100 microM for 24-72 h was analyzed using flow cytometry. Simvastatin significantly reduced the adhesion of all ovarian Cancer cells and HT29 to HMCs (P

Britta Janina Wagner - One of the best experts on this subject based on the ideXlab platform.

  • simvastatin reduces tumor cell adhesion to human peritoneal mesothelial cells by decreased expression of vcam 1 and β1 integrin
    International Journal of Oncology, 2011
    Co-Authors: Britta Janina Wagner, Stefan Löb, Dennis Lindau, Helen Hörzer, Brigitte Gückel, Gerd Klein, Jörg Glatzle, Hans-georg Rammensee, Björn L.d.m. Brücher, Alfred Königsrainer
    Abstract:

    Peritoneal carcinomatosis describes Cancer metastasis onto the surface of the Peritoneum. It is frequently caused by ovarian and colorectal Cancer. Once a tumor has penetrated the Peritoneum, Cancer cells disseminate into the abdominal cavity. Additionally, surgery can account for the spread of free tumor cells. Their subsequent adhesion to mesothelial cells (HMCs) initiates peritoneal carcinomatosis. Therefore, this study analyzed the effect of simvastatin on tumor cell adherence. HMCs were isolated from human greater omentum. Fluorescence-labeled tumor cells (SKOV-3, OvCar-29, OAW42, FraWu; ovarian/HT29; colorectal) were incubated on confluent mesothelial monolayers with 10 microM simvastatin for 48 h. Adhesion was quantified using a fluorescence reader. Expression of the adhesion molecules VCAM-1, ICAM-1 and beta1 integrin chain under the influence of simvastatin 0.1-100 microM for 24-72 h was analyzed using flow cytometry. Simvastatin significantly reduced the adhesion of all ovarian Cancer cells and HT29 to HMCs (PVCAM-1 on HMCs. ICAM-1 and beta1 integrin chain expression on ovarian Cancer cells was also clearly reduced. By contrast, the expression of the analyzed adhesion molecules on HT29 cells remained unchanged. Simvastatin clearly inhibits tumor cell adhesion to HMCs. In the case of ovarian Cancer cell lines it appears to be mediated by decreased expression of both VCAM-1 on HMCs and the integrin alpha4beta1 on tumor cells. As an example of adhesion molecule down-regulating drugs, simvastatin may provide a novel therapeutic approach to the prevention of peritoneal carcinomatosis.

  • Simvastatin reduces tumor cell adhesion to human peritoneal mesothelial cells by decreased expression of VCAM-1 and β1 integrin
    International journal of oncology, 2011
    Co-Authors: Britta Janina Wagner, Stefan Löb, Dennis Lindau, Helen Hörzer, Brigitte Gückel, Gerd Klein, Jörg Glatzle, Hans-georg Rammensee, Björn L.d.m. Brücher, Alfred Königsrainer
    Abstract:

    Peritoneal carcinomatosis describes Cancer metastasis onto the surface of the Peritoneum. It is frequently caused by ovarian and colorectal Cancer. Once a tumor has penetrated the Peritoneum, Cancer cells disseminate into the abdominal cavity. Additionally, surgery can account for the spread of free tumor cells. Their subsequent adhesion to mesothelial cells (HMCs) initiates peritoneal carcinomatosis. Therefore, this study analyzed the effect of simvastatin on tumor cell adherence. HMCs were isolated from human greater omentum. Fluorescence-labeled tumor cells (SKOV-3, OvCar-29, OAW42, FraWu; ovarian/HT29; colorectal) were incubated on confluent mesothelial monolayers with 10 microM simvastatin for 48 h. Adhesion was quantified using a fluorescence reader. Expression of the adhesion molecules VCAM-1, ICAM-1 and beta1 integrin chain under the influence of simvastatin 0.1-100 microM for 24-72 h was analyzed using flow cytometry. Simvastatin significantly reduced the adhesion of all ovarian Cancer cells and HT29 to HMCs (P

Brigitte Gückel - One of the best experts on this subject based on the ideXlab platform.

  • simvastatin reduces tumor cell adhesion to human peritoneal mesothelial cells by decreased expression of vcam 1 and β1 integrin
    International Journal of Oncology, 2011
    Co-Authors: Britta Janina Wagner, Stefan Löb, Dennis Lindau, Helen Hörzer, Brigitte Gückel, Gerd Klein, Jörg Glatzle, Hans-georg Rammensee, Björn L.d.m. Brücher, Alfred Königsrainer
    Abstract:

    Peritoneal carcinomatosis describes Cancer metastasis onto the surface of the Peritoneum. It is frequently caused by ovarian and colorectal Cancer. Once a tumor has penetrated the Peritoneum, Cancer cells disseminate into the abdominal cavity. Additionally, surgery can account for the spread of free tumor cells. Their subsequent adhesion to mesothelial cells (HMCs) initiates peritoneal carcinomatosis. Therefore, this study analyzed the effect of simvastatin on tumor cell adherence. HMCs were isolated from human greater omentum. Fluorescence-labeled tumor cells (SKOV-3, OvCar-29, OAW42, FraWu; ovarian/HT29; colorectal) were incubated on confluent mesothelial monolayers with 10 microM simvastatin for 48 h. Adhesion was quantified using a fluorescence reader. Expression of the adhesion molecules VCAM-1, ICAM-1 and beta1 integrin chain under the influence of simvastatin 0.1-100 microM for 24-72 h was analyzed using flow cytometry. Simvastatin significantly reduced the adhesion of all ovarian Cancer cells and HT29 to HMCs (PVCAM-1 on HMCs. ICAM-1 and beta1 integrin chain expression on ovarian Cancer cells was also clearly reduced. By contrast, the expression of the analyzed adhesion molecules on HT29 cells remained unchanged. Simvastatin clearly inhibits tumor cell adhesion to HMCs. In the case of ovarian Cancer cell lines it appears to be mediated by decreased expression of both VCAM-1 on HMCs and the integrin alpha4beta1 on tumor cells. As an example of adhesion molecule down-regulating drugs, simvastatin may provide a novel therapeutic approach to the prevention of peritoneal carcinomatosis.

  • Simvastatin reduces tumor cell adhesion to human peritoneal mesothelial cells by decreased expression of VCAM-1 and β1 integrin
    International journal of oncology, 2011
    Co-Authors: Britta Janina Wagner, Stefan Löb, Dennis Lindau, Helen Hörzer, Brigitte Gückel, Gerd Klein, Jörg Glatzle, Hans-georg Rammensee, Björn L.d.m. Brücher, Alfred Königsrainer
    Abstract:

    Peritoneal carcinomatosis describes Cancer metastasis onto the surface of the Peritoneum. It is frequently caused by ovarian and colorectal Cancer. Once a tumor has penetrated the Peritoneum, Cancer cells disseminate into the abdominal cavity. Additionally, surgery can account for the spread of free tumor cells. Their subsequent adhesion to mesothelial cells (HMCs) initiates peritoneal carcinomatosis. Therefore, this study analyzed the effect of simvastatin on tumor cell adherence. HMCs were isolated from human greater omentum. Fluorescence-labeled tumor cells (SKOV-3, OvCar-29, OAW42, FraWu; ovarian/HT29; colorectal) were incubated on confluent mesothelial monolayers with 10 microM simvastatin for 48 h. Adhesion was quantified using a fluorescence reader. Expression of the adhesion molecules VCAM-1, ICAM-1 and beta1 integrin chain under the influence of simvastatin 0.1-100 microM for 24-72 h was analyzed using flow cytometry. Simvastatin significantly reduced the adhesion of all ovarian Cancer cells and HT29 to HMCs (P

Björn L.d.m. Brücher - One of the best experts on this subject based on the ideXlab platform.

  • simvastatin reduces tumor cell adhesion to human peritoneal mesothelial cells by decreased expression of vcam 1 and β1 integrin
    International Journal of Oncology, 2011
    Co-Authors: Britta Janina Wagner, Stefan Löb, Dennis Lindau, Helen Hörzer, Brigitte Gückel, Gerd Klein, Jörg Glatzle, Hans-georg Rammensee, Björn L.d.m. Brücher, Alfred Königsrainer
    Abstract:

    Peritoneal carcinomatosis describes Cancer metastasis onto the surface of the Peritoneum. It is frequently caused by ovarian and colorectal Cancer. Once a tumor has penetrated the Peritoneum, Cancer cells disseminate into the abdominal cavity. Additionally, surgery can account for the spread of free tumor cells. Their subsequent adhesion to mesothelial cells (HMCs) initiates peritoneal carcinomatosis. Therefore, this study analyzed the effect of simvastatin on tumor cell adherence. HMCs were isolated from human greater omentum. Fluorescence-labeled tumor cells (SKOV-3, OvCar-29, OAW42, FraWu; ovarian/HT29; colorectal) were incubated on confluent mesothelial monolayers with 10 microM simvastatin for 48 h. Adhesion was quantified using a fluorescence reader. Expression of the adhesion molecules VCAM-1, ICAM-1 and beta1 integrin chain under the influence of simvastatin 0.1-100 microM for 24-72 h was analyzed using flow cytometry. Simvastatin significantly reduced the adhesion of all ovarian Cancer cells and HT29 to HMCs (PVCAM-1 on HMCs. ICAM-1 and beta1 integrin chain expression on ovarian Cancer cells was also clearly reduced. By contrast, the expression of the analyzed adhesion molecules on HT29 cells remained unchanged. Simvastatin clearly inhibits tumor cell adhesion to HMCs. In the case of ovarian Cancer cell lines it appears to be mediated by decreased expression of both VCAM-1 on HMCs and the integrin alpha4beta1 on tumor cells. As an example of adhesion molecule down-regulating drugs, simvastatin may provide a novel therapeutic approach to the prevention of peritoneal carcinomatosis.

  • Simvastatin reduces tumor cell adhesion to human peritoneal mesothelial cells by decreased expression of VCAM-1 and β1 integrin
    International journal of oncology, 2011
    Co-Authors: Britta Janina Wagner, Stefan Löb, Dennis Lindau, Helen Hörzer, Brigitte Gückel, Gerd Klein, Jörg Glatzle, Hans-georg Rammensee, Björn L.d.m. Brücher, Alfred Königsrainer
    Abstract:

    Peritoneal carcinomatosis describes Cancer metastasis onto the surface of the Peritoneum. It is frequently caused by ovarian and colorectal Cancer. Once a tumor has penetrated the Peritoneum, Cancer cells disseminate into the abdominal cavity. Additionally, surgery can account for the spread of free tumor cells. Their subsequent adhesion to mesothelial cells (HMCs) initiates peritoneal carcinomatosis. Therefore, this study analyzed the effect of simvastatin on tumor cell adherence. HMCs were isolated from human greater omentum. Fluorescence-labeled tumor cells (SKOV-3, OvCar-29, OAW42, FraWu; ovarian/HT29; colorectal) were incubated on confluent mesothelial monolayers with 10 microM simvastatin for 48 h. Adhesion was quantified using a fluorescence reader. Expression of the adhesion molecules VCAM-1, ICAM-1 and beta1 integrin chain under the influence of simvastatin 0.1-100 microM for 24-72 h was analyzed using flow cytometry. Simvastatin significantly reduced the adhesion of all ovarian Cancer cells and HT29 to HMCs (P

Hans-georg Rammensee - One of the best experts on this subject based on the ideXlab platform.

  • simvastatin reduces tumor cell adhesion to human peritoneal mesothelial cells by decreased expression of vcam 1 and β1 integrin
    International Journal of Oncology, 2011
    Co-Authors: Britta Janina Wagner, Stefan Löb, Dennis Lindau, Helen Hörzer, Brigitte Gückel, Gerd Klein, Jörg Glatzle, Hans-georg Rammensee, Björn L.d.m. Brücher, Alfred Königsrainer
    Abstract:

    Peritoneal carcinomatosis describes Cancer metastasis onto the surface of the Peritoneum. It is frequently caused by ovarian and colorectal Cancer. Once a tumor has penetrated the Peritoneum, Cancer cells disseminate into the abdominal cavity. Additionally, surgery can account for the spread of free tumor cells. Their subsequent adhesion to mesothelial cells (HMCs) initiates peritoneal carcinomatosis. Therefore, this study analyzed the effect of simvastatin on tumor cell adherence. HMCs were isolated from human greater omentum. Fluorescence-labeled tumor cells (SKOV-3, OvCar-29, OAW42, FraWu; ovarian/HT29; colorectal) were incubated on confluent mesothelial monolayers with 10 microM simvastatin for 48 h. Adhesion was quantified using a fluorescence reader. Expression of the adhesion molecules VCAM-1, ICAM-1 and beta1 integrin chain under the influence of simvastatin 0.1-100 microM for 24-72 h was analyzed using flow cytometry. Simvastatin significantly reduced the adhesion of all ovarian Cancer cells and HT29 to HMCs (PVCAM-1 on HMCs. ICAM-1 and beta1 integrin chain expression on ovarian Cancer cells was also clearly reduced. By contrast, the expression of the analyzed adhesion molecules on HT29 cells remained unchanged. Simvastatin clearly inhibits tumor cell adhesion to HMCs. In the case of ovarian Cancer cell lines it appears to be mediated by decreased expression of both VCAM-1 on HMCs and the integrin alpha4beta1 on tumor cells. As an example of adhesion molecule down-regulating drugs, simvastatin may provide a novel therapeutic approach to the prevention of peritoneal carcinomatosis.

  • Simvastatin reduces tumor cell adhesion to human peritoneal mesothelial cells by decreased expression of VCAM-1 and β1 integrin
    International journal of oncology, 2011
    Co-Authors: Britta Janina Wagner, Stefan Löb, Dennis Lindau, Helen Hörzer, Brigitte Gückel, Gerd Klein, Jörg Glatzle, Hans-georg Rammensee, Björn L.d.m. Brücher, Alfred Königsrainer
    Abstract:

    Peritoneal carcinomatosis describes Cancer metastasis onto the surface of the Peritoneum. It is frequently caused by ovarian and colorectal Cancer. Once a tumor has penetrated the Peritoneum, Cancer cells disseminate into the abdominal cavity. Additionally, surgery can account for the spread of free tumor cells. Their subsequent adhesion to mesothelial cells (HMCs) initiates peritoneal carcinomatosis. Therefore, this study analyzed the effect of simvastatin on tumor cell adherence. HMCs were isolated from human greater omentum. Fluorescence-labeled tumor cells (SKOV-3, OvCar-29, OAW42, FraWu; ovarian/HT29; colorectal) were incubated on confluent mesothelial monolayers with 10 microM simvastatin for 48 h. Adhesion was quantified using a fluorescence reader. Expression of the adhesion molecules VCAM-1, ICAM-1 and beta1 integrin chain under the influence of simvastatin 0.1-100 microM for 24-72 h was analyzed using flow cytometry. Simvastatin significantly reduced the adhesion of all ovarian Cancer cells and HT29 to HMCs (P